Hematologic Malignancies & Cellular Therapy


Overview & Treatment

GoodeAs leaders in hematologic oncology, stem cell and bone marrow transplantation, and immunotherapy, Duke Cancer Institute’s Hematologic Malignancies and Cellular Therapy (HMCT) disease group is internationally recognized for its novel approaches to treating leukemia, lymphoma, myeloma and other life threatening blood-related cancers.

We promote health and improve lives by preventing, diagnosing and treating blood cancers through integrated, innovative, and holistic patient care, education and research.

We offer a  broad selection of treatment options, including access to national and investigator-initiated clinical trials.

More Information


The Duke Hematologic Malignancies & Cellular Therapy (HMCT) Research Program is a multidisciplinary basic, translational, and clinical research program whose overall goal is to improve outcomes for patients with hematologic malignancies.

Our research program can be broadly divided into the following research areas: 

  • Basic research into the tumor microenvironment, bone marrow niche
  • Basic understanding of immunity, both inate and adaptive
  • Genomics, including a genomics core
  • Cellular therapies such as hematopoietic stem cells, adoptive immunotherapy with selected T cells, NK cells, dendritic cell vaccines, gamma delta T cells
  • Graft-versus-host disease and graft-versus-leukemia effects
  • Cell signaling pathways in normal and tumor cells


Clinical Trials

We offer our patients access to more than 50 active clinical trials specific to hematologic malignancies and transplantation.

These trials range from securely storing your medical information in an outcomes-reporting registry, to sample repositories, and to national clinical trials and investigator-initiated trials designed to prevent, detect, or treat your underlying disease with the most advanced treatment methods.

Your participation may help you and others in the future. 

Some of these trials are only offered at the Duke Cancer Institute. As a result, we offer a broad selection of treatment options to our patients, including some who are not considered candidates for treatment elsewhere. Your participation in a clinical trial may help you and others in the future. 


Blood Cancer Specialists

We discover, develop and deliver the future of cancer care . . . now.

Leukemia & MDS Program
Carlos DeCastro, MD
Harry Erba, MD, PhD
Thomas Leblanc, MD
Guiyun Zhou, MD

Myeloproliferative Neoplasms Program
Harry Erba, MD, PhD
Lindsay Rein, MD

Lymphoma & CLL Program
Danielle Brander, MD 
Colin Champ, MD (Rad Onc)
Ahmed Galal, MD
Matthew McKinney, MD
Alexandra Stefanovic, MD
Jie Wang, MD
Christopher Kelsey, MD (Rad Onc)
Samantha Schmidtke, NP
Andrea Sitlinger, MD
Jennifer Snyder, NP
Amy Tammenga, FNP
Elizabeth Zechinati, NP
Guiyun Zhou, MD

Yubin Kang, MD
Gwynn Long, MD
Richard Lopez, MD
Stefanie Sarantopoulos, MD, PhD
Anthony Sung, MD
Margaret “Peggy” Eren, NP
Tanya Helms, PA
Therese Hennig, PA
Hematologic Malignancies Program
Duke Cancer Center Raleigh

Suzanne Kirby, MD, PhD
Alison Pereklita, PA